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Hepatocellular carcinoma (HCC) is one of the very few major cancers 
in which the aetiology can be identified in individual patients. Thus, 
in contrast to some cancers in which risk factors (diet, smoking, 
genetic factors) increase the risk of developing a particular cancer, 
the presence of an identifiable underlying liver disease in the majority 
of patients with HCC is readily apparent. Globally, chronic viral 
hepatitis (B and C) with their associated hepatitis and/or cirrhosis 
account for nearly 75% of all cases of HCC.[1] One of the important 
consequences of this observation is that HCC may be more readily 
preventable than other major cancers.
It has already been well established that vaccination against 
hepatitis B virus (HBV) is an effective strategy in preventing HBV-
related HCC. Thus the introduction of universal infant vaccination 
against HBV infection in Taiwan in the early 1980s has been shown 
to be associated with a dramatic and statistically significant decrease 
in childhood HCC.[2] These cohorts of individuals vaccinated in the 
1980s continue to be monitored and it is expected that their lower 
incidences of HCC will continue on into their adulthood and their 
protection is expected to be lifelong. Unfortunately, there is not yet an 
effective vaccine against the hepatitis C virus (HCV), although public 
health efforts, such as screening of donated blood and education 
about the risks of blood-borne infection have been associated with 
steadily decreasing rates of new HCV infections in the developed 
Western world.
However, a challenge remains for those persons who are already 
chronically infected with HBV or HCV, as they are already at risk of 
developing HCC at some point. Over the last 3 decades enormous 
strides have been made in developing effective antiviral therapies 
against these agents, which raises the question of whether antiviral 
therapy may decrease their risk of HCC.
Hepatitis B
Antiviral therapy for chronic HBV infection has evolved over the 
last several decades, from interferon and a variety of other less 
effective agents, to now include nucleoside or nucleotide analogues 
with high potency and barriers to resistance. The use of alpha 
interferons (initially standard interferon-alpha (IFNα), and more 
recently pegylated IFNα (PEG-IFNα)) appears to be associated with 
achieving immune control of HBV in about 30 - 40% of cases.[3] 
This is followed by viral cure or loss of hepatitis B surface antigen 
(HBsAg) in ~10% of treated individuals. However, the use of 
interferons has been limited because of their substantial side-effect 
profile and the need for administration by subcutaneous injection. 
The first nucleoside analogue to be introduced was lamivudine, an 
agent initially developed for use against HIV infection. Whereas 
lamivudine is moderately potent against HBV, viral resistance 
emerges quite rapidly and limits the prolonged use of this agent 
as monotherapy. The next drug to be developed against HBV was 
adefovir, which was somewhat less potent than lamivudine, but also 
somewhat less likely to result in emergence of treatment-resistant 
viral variants. Telbivudine is widely used in some countries but has 
a resistance profile similar to lamivudine. The current mainstream 
agents used to control HBV infection are tenofovir and entecavir, 
which have now been available for 5 - 10 years.
There is currently very little evidence to suggest that the use of 
interferon is associated with a reduced rate of HBV-related HCC.[4] 
However, it is not clear that appropriate studies have been done on 
patients with chronic hepatitis B treated with interferon, focusing 
on those who have cleared HBsAg or maintained viral suppression 
after therapy.
Lamivudine is the nucleoside analogue agent that has been in 
use for the longest time, and has therefore permitted the most 
comprehensive study of its putative benefits in preventing HCC. 
The best evidence suggesting that antiviral therapy may be of 
benefit is a large prospective, randomised, placebo-controlled trial of 
lamivudine therapy in patients with advanced liver disease associated 
with HBV infection.[5] The study enrolled 651 patients with chronic 
HBV infection and advanced hepatic fibrosis. The patients were 
randomised to receive either lamivudine or an oral placebo. The 
planned outcomes of the study were clinically apparent events such 
as hepatic decompensation, death, and the development of HCC. 
The study was halted early upon the recommendation of a data-
safety monitoring board, because of an early and readily apparent 
difference in morbidity and mortality rates among patients in the 
different treatment groups. While an analysis of the data showed a 
statistically significant reduction in rates of hepatic decompensation 
and death, the difference in HCC rates was of borderline statistical 
significance at the time that the study was stopped. Thus, 3.9% 
of patients receiving lamivudine developed HCC compared with 
7.4% on placebo (p=0.047). It is certainly possible that if this study 
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had been continued this trend towards a significantly lower rate of 
HCC may have continued and become more significant. One of the 
challenges in showing that lamivudine reduces the risk of HCC is the 
relatively high rate of development of viral resistance associated with 
loss of viral control, making results difficult to interpret.[5,6]
Cohort studies of patients receiving lamivudine therapy have had 
mixed results. Thus, Kurokawa et al.[7] reported on their experience 
of 293 patients receiving lamivudine for an average time of 67.6 
months. Although this study did not include an untreated control 
group for comparison, the authors did find that the incidence of HCC 
was reduced in those patients achieving a maintained virological 
response, compared with those in whom HBV was not well controlled 
due to the emergence of viral resistance. A similar result was achieved 
in a study from Korea, reported by Eun et al.[8] Among patients 
with HBV-induced compensated cirrhosis, HCC occurred in 4.9% 
of cases with maintained viral response, 11.8% in those with viral 
breakthrough, and 19.4% of those with a suboptimal response to 
lamivudine. This study included an untreated control group that had 
an HCC rate of 25.0% after a mean follow-up of 6.1 years.
More recently, entecavir and tenofovir have become widely used 
as the main antiviral agents to control HBV infection.[30] Both agents 
appear to have a much higher barrier to resistance than lamivudine, 
and seem to be reasonably well tolerated. Randomised controlled 
trials of these agents have focused on their ability to control HBV 
infection and not so much on clinical outcomes or HCC development.
Hosaka et al.[9] reported on their experience with long-
term entecavir treatment in Japan. They assembled a cohort of 
1 615 patients with chronic HBV infection. Of these, 472 mono-
infected patients with HBV received entecavir. Their outcomes 
were compared with 1 143 mono-infected patients who did not 
receive antiviral therapy. The cumulative HCC incidence rates 
at 5 years were 3.7% and 13.7% for the entecavir group and the 
controls, respectively (p<0.001). They found this protective effect to 
be even greater in subsets of patients at higher risk of HCC, based 
on calculation of a propensity score, including risk factors such as 
age, gender, and the presence of cirrhosis, HBeAg and HBV DNA 
levels. Papatheodoridis et al.[10] reported on the outcomes of 1 666 
patients recruited from multiple sites in Europe. They were treated 
with entecavir or tenofovir, and essentially all patients achieved 
a maintained virological response (i.e. undetectable serum HBV 
DNA) by year 5. Despite this excellent viral control, HCC still 
occurred at a frequency of 8.7% after the 5 years of treatment. 
Again, there was no untreated comparison group with which to 
compare the frequency of HCC, but it is clear that development of 
liver cancer is not completely suppressed by antiviral therapy.
A similar experience with tenofovir has not yet been reported, 
perhaps because it has not yet been used against HBV for as long as 
lamivudine or entecavir. Marcellin et al. [11] reported on a long-term 
follow-up study of 641 patients initially randomised into one of the 
pivotal studies done to achieve licensure of tenofovir for HBV. The 
main finding of this study was that almost all patients achieved a 
maintained virological response with dramatic improvements in their 
liver disease, including the apparent regression of cirrhosis in 74% of 
those who had biopsy-proven cirrhosis at baseline. It was noted in 
this report that seven patients (1.0%) died from malignant disease 
,which included three with HCC, one with cholangiocarcinoma, and 
three with cancers at other sites.
Most of the data related to risk reduction of HCC have been 
gathered in Asia, although a recent cohort study reported from 
the USA indicated some benefit of antiviral therapy. Thus, Gordon 
et al.[12] recently described their analysis of electronic health records 
from 2 671 adult individuals (49% of whom were Asian) being 
tracked in the Chronic Hepatitis Cohort Study (CHeCS).[13] Of these, 
820 had received some form of antiviral therapy, including possibly 
IFN-α, while the remaining 1 851 were untreated. Patients who 
received antiviral therapy had a lower risk of HCC than those who 
did not (AHR 0.39; 95% confidence interval 0.27 - 0.56; p<0.001).
In a review article summarising data on prevention of HBV-related 
HCC, Lai and Yuen[14] noted that, while long-term follow-up studies 
of interferon-treated patients show inconsistent results, beneficial 
effects could be observed in those treated with nucleoside analogues, 
particularly among those with pre-existing cirrhosis and those who 
achieved substantial viral control on therapy.
At least two meta-analyses have been done of the anti-cancer 
benefits of antiviral therapy in chronic hepatitis B.[15,16] Interestingly, 
one of these found a greater reduction in HCC in patients treated 
with lamivudine compared with those who were not treated, and even 
more substantial benefits in patients receiving the newer nucleoside 
analogues, whereas the second meta-analysis showed only a marginal 
benefit, limited to those patients with cirrhosis, possibly because the 
latter study only included controlled trials, whereas other analyses 
have also included cohort studies.
Hepatitis D
The hepatitis D virus (HDV) is an RNA virus that requires HBsAg 
to complete its replicative cycle. Therefore, it only infects individuals 
who are already infected with HBV.[17] HDV appears to aggravate 
HBV liver disease, with a higher occurrence of cirrhosis. Because 
of this higher frequency of cirrhosis, HCC also appears to be more 
common.[18] The mainstay of therapy for chronic HDV infection 
remains IFNα, often given for very prolonged periods or even 
indefinitely. There have, so far, been no reliable studies of HDV 
therapy aimed at preventing the development of HCC.
Hepatitis A and hepatitis E
There is currently no evidence that infection with either of these 
viral agents increases the risk of subsequent development of HCC. 
This is likely to be because both agents are predominantly associated 
with acute, self-limited infection. Indeed, hepatitis A viral infection 
never becomes chronic and, while hepatitis E viral infection may be 
chronic, this is a rare occurrence and tends to occur predominantly 
in immunosuppressed persons.
Hepatitis C
Chronic HCV infection appears to be associated with about 30% of 
HCCs worldwide, although in some regions, including Europe and the 
United States, it is the leading underlying cause of HCC.[19] Measures 
to prevent HCV-related HCC include prevention of HCV infection in 
the first place (primary prevention), control of elimination of HCV 
infection (secondary prevention), and treatment of HCV after HCC 
has already developed and been treated, with the hope of preventing 
new tumours from developing (tertiary prevention).
Public health efforts to reduce the incidence of HCV infection 
have been remarkably successful. Post-transfusion HCV is now an 
extremely rare event in the developed world, where transfusions of 
blood and blood products was a major source of hepatitis C infection 
as recently as three decades ago.[20] In the USA, the overall number 
of acute hepatitis C cases has been declining steadily since 1992, 
presumably because of greater awareness of the risk of blood-borne 
infections among injection drug users. Interestingly, however, there 
may be a recent spike in incidence of acute hepatitis C infection 
related to the ongoing epidemic of heroin use in the USA but 
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incidence rates are still way below those seen in previous decades.[21] 
Unfortunately, little progress has been made in developing a vaccine 
against HCV, but tremendous strides have been taken in developing 
effective antiviral therapy, as described below.
In contrast to hepatitis B, the evidence is substantial that effective 
treatment of hepatitis C can reduce the risk of HCC. It has been 
estimated that about 20% of patients with chronic HCV infection 
will go on to develop cirrhosis, and it is these patients with advanced 
liver disease who are at greatest risk of hepatic decompensation and 
HCC. The first suggestion that antiviral therapy might be effective 
in preventing HCC came from a study of interferon, conducted in 
Japan and reported in 1995,[22] which showed a lower rate of HCC 
among patients with HCV-related cirrhosis who were treated with 
IFNα compared with those who were not, in a randomised controlled 
trial, although this study did not really differentiate outcomes in 
virological responders and non-responders. Over the next decade 
or so, there followed a series of reports based on retrospective 
studies showing that successful treatment of HCV with interferon, 
achieving a sustained virological response (SVR), was associated 
with substantially lower rates of HCC than among those who were 
untreated or those who were treated but did not achieve an SVR.[23]
The only other randomised controlled trials to be done on this 
topic were trials of long-term maintenance therapy using alpha-
interferon in patients who had previously not responded virologically 
to a course of interferon treatment. The HALT-C Trial (Hepatitis 
C Antiviral Long-term Therapy against Cirrhosis) was a large 
randomised controlled trial carried out at multiple sites within the 
USA. More than 1 000 patients were enrolled in the trial[24] and it 
was one of only a few prospective randomised controlled trials aimed 
at trying to reduce the incidence of HCC with alpha-interferon as 
antiviral therapy. 
This NIH-funded study randomised patients with HCV infection 
and advanced fibrosis (bridging hepatic fibrosis or cirrhosis) to 
receive long-term maintenance therapy with a low dose of PEG-
IFNα or to remain untreated for a period of 4 years. The initial report 
from this study showed that antiviral therapy did not reduce the 
rate of either hepatic decompensation or HCC.[24] A more prolonged 
follow-up of these cohorts showed that a slightly lower rate of HCC 
occurred in the interferon-treated patients – interestingly, this 
difference appeared several years after stopping therapy.[25] Perhaps 
the best evidence to emerge from the HALT-C Trial in this regard 
was a comparison of liver-related outcomes after 7 - 8 years of 
follow-up among patients who did not respond to therapy. Morgan 
et al.[26] found that patients treated in HALT-C, but who achieved an 
SVR, had significantly lower rates of hepatic decompensation, liver 
transplantation, or HCC than patients who remained non-responders 
to interferon after a follow up period of 7 - 8 years.
George et al.[27] reported on a 5-year follow-up of 150 patients 
achieving SVR. Among them, 49 had liver biopsies done prior to 
therapy and again after the 5-year period of follow-up. The degree 
of hepatic fibrosis declined substantially in almost all patients. 
Interestingly the only two patients in whom fibrosis was not reduced 
went on to develop HCC.
Other large cohort studies were reported by Aleman et al.,[28] 
based on patients in Sweden, and by Van der Meer et al.,[29] based 
on patients in several countries in Europe and Canada. The rates of 
HCC are summarised in Tables 1 and 2 , but were significantly lower 
in patients achieving SVR compared with those who were either 
untreated on did not respond to therapy.
As with hepatitis B, meta-analyses have been conducted to assess 
the impact of antiviral therapy in preventing HCV-related HCC. 
One of these used Cochrane methodology, focused on randomised 
controlled trials, and found statistically significant overall effects 
(p=0.007) when comparing cirrhotic patients achieving SVR with 
controls.[30] A second meta-analysis looked at patients with advanced 
fibrosis or cirrhosis, and included both randomised controlled trials 
and cohort studies, and similarly found a statistically significant 
overall effect both in cirrhotics and patients will all degrees of fibrosis 
(p<0.001).[31]
Most recently, concerns have been raised about higher than 
estimated rates of occurrence and recurrence of HCC after viral 
clearance with the new direct-acting antiviral agents, particularly in 
patients with cirrhosis.[32] These preliminary observations require 
further study in order to be validated.
Conclusion
In summary, antiviral treatment for viral hepatitis appears to have 
benefits in decreasing the risk of HCC in chronically infected 
patients. This benefit is most pronounced in patients with chronic 
hepatitis C and advanced hepatic fibrosis or cirrhosis in patients 
achieving viral clearance, while it seems much more marginal in 
patients with chronic hepatitis B, where antiviral therapy usually 
results in viral suppression rather than elimination.
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